
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MONOPRIL | Bristol Myers Squibb | N-019915 DISCN | 1991-05-16 | 3 products, RLD |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MONOPRIL-HCT | Bristol Myers Squibb | N-020286 DISCN | 1994-11-30 | 2 products, RLD |
Brand Name | Status | Last Update |
|---|---|---|
| fosinopril sodium | ANDA | 2025-10-10 |
| fosinopril sodium and hydrochlorothiazide | ANDA | 2024-04-28 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | — | — | 4 | 4 |
| Disease | D004194 | EFO_0000408 | R69 | — | — | — | — | 1 | 1 |
| Drug common name | Fosinopril |
| INN | fosinopril |
| Description | Fosinopril is a phosphinate ester-containing N-acyl derivative of (4S)-cyclohexyl-L-proline. It is used for the treatment of hypertension and heart failure. A pro-drug, it is hydrolysed in vivo to the corresponding phosphininc acid, fosinoprilat, which is the active metabolite. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor, a prodrug and an antihypertensive agent. It is a phosphinic ester and a L-proline derivative. It is functionally related to a fosinoprilat. It is a conjugate acid of a fosinopril(1-). |
| Classification | Small molecule |
| Drug class | phosphoro-derivatives; antihypertensives (ACE inhibitors) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C |
| PDB | — |
| CAS-ID | 98048-97-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3039598 |
| ChEBI ID | — |
| PubChem CID | 55891 |
| DrugBank | DB00492 |
| UNII ID | R43D2573WO (ChemIDplus, GSRS) |











